On April 27, AMCP joined a broad coalition of health care stakeholders in urging Congressional leaders to protect American's access to COVID-19 testing, treatments, and vaccines, regardless of insurance status - by replenishing the COVID-19 Uninsured Relief Fund.
On March 25, AMCP joined a diverse coalition of pharmacy stakeholders in expressing support for the Equitable Community Access for Pharmacists Services Act. This bill would permanently authorize pharmacists' ability to provide health care services during public health emergencies.
On April 19, AMCP joined a pharmacy stakeholder letter addressed to the Biden administration's COVID-19 czar, Dr. Ashish Jha. The letter urged the Biden administration to allow qualified pharmacists to prescribe oral antivirals to treat COVID-19 and maintain PREP Act services provided by pharmacists.
On March 18, AMCP provided comments to the HHS Office of the National Coordinator for Health Information Technology regarding electronic prior authorization.
On March 9, AMCP joined 13 pharmacy organizations in urging President Biden to authorize pharmacists to order and administer oral antivirals to treat COVID-19 as part of the administration's Test to Treat policy.
AMCP provides feedback on CMS's proposal to redefine negotiated price as the lowest possible payment that a Part D plan will make to a pharmacy, inclusive of all price concessions.
On March 3, AMCP responded to a Request for Information from the Healthy Futures Subcommittee on Modernization, supporting legislative and regulatory solutions to remove barriers to coverage and payment for Digital Therapeutics in the Medicare program.
On Feb. 14, AMCP joined a pharmacy stakeholder letter supporting Dr. Robert Califf's nomination for FDA Commissioner, a post he previously held in 2016.
On Feb. 9, AMCP submitted comments to CMS supporting the agency's proposal to cover anti-amyloid monoclonal antibodies through the Coverage with Evidence Development pathway.
On Jan. 11, CMS released a proposed coverage decision that would cover the costs of monoclonal antibody treatments for Alzheimer's Disease patients only if they are enrolled in clinical trials.
On Jan. 6, CMS released a proposed rule that would require pharmacy price concessions be passed to patients at the point-of-sale and reinstate detailed MLR reporting requirements.
On Dec. 28, CMS released a proposed rule that would, in part, propose that adverse tiering is presumptively discriminatory and require that QHP issues offer more standardized plan options.
AMCP joined other organizations to call on the business community to support the new federal requirement that those working for companies with more than 100 employees be vaccinated for COVID.
On Nov. 2, AMCP joined a pharmacy stakeholder coalition letter to CMS requesting the agency use its PREP Act authority to establish payment mechanisms for Medicare and Medicaid to reimburse pharmacists for COVID-19 patient assessment services.
On Oct. 28, AMCP joined a pharmacy stakeholder coalition letter to HHS requesting authorizations for pharmacists, pharmacy technicians and interns to order and administer antiviral medications and flu tests.
In October, AMCP joined other pharmacy organizations in supporting the Pharmacist's Fundamental Responsibilities and Rights released by APhA and the National Alliance of State Pharmacy Associations (NASPA). These principles focus on pharmacists' responsibilities and the workplace conditions necessary to fulfill those responsibilities.
AMCP submitted comments on the proposed FDA Prescription Drug User Fee Act Reauthorization commitment letter, supporting the agency's plans to increase resources for approval of cell and gene therapies and continued exploration of uses for real-world evidence in regulatory decision-making.